Vor Biopharma’s (VOR) Buy Rating Reiterated at HC Wainwright

Nov 11, 2024 · HC Wainwright reaffirmed their buy rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research note issued to investors on Friday,Benzinga reports. …

$10.00
OFF

Vor Biopharma (NYSE:VOR) Earns Buy Rating From HC Wainwright

4 weeks from now

Nov 8, 2024 · A number of other research firms also recently weighed in on VOR. Barclays reduced their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an …

marketbeat.com

$17.50
OFF

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating Of “Buy” …

4 weeks from now

Nov 22, 2024 · HC Wainwright reissued a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research note on Friday, November 8th. ... Vor Biopharma Daily …

defenseworld.net

$17.50
OFF

Vor Biopharma Stock Holds Price Target, Buy Rating On Positive …

4 weeks from now

Sep 6, 2024 · On Friday, H.C. Wainwright maintained a Buy rating on shares of Vor Biopharma Inc. (NASDAQ:VOR) with a price target of $17.50, following the company's latest clinical study …

investing.com

98%
OFF

Vor Biopharma (VOR) Stock Forecast And Price Target 2024

4 weeks from now

5 days ago · Reiterated Rating: Buy Buy: $17.50 $17.50 +1,649.98%: 12/9/2024: Wedbush. 4 of 5 stars ... Vor Biopharma has been rated by research analysts at HC Wainwright, JMP …

marketbeat.com

$11.36
OFF

Vor Biopharma Inc. (NYSE:VOR) Receives $11.36 Consensus

4 weeks from now

Dec 17, 2024 · Robert W. Baird decreased their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating on the stock in a research note on Friday, …

marketbeat.com

$26.00
OFF

H.C. Wainwright Initiates A Buy Rating On Vor Biopharma (VOR)

4 weeks from now

H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage with a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $26.00. The company's …

advfn.com

$20.00
OFF

H.C. Wainwright Sticks To Its Buy Rating For Vor Biopharma (VOR)

4 weeks from now

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Vor Biopharma (VOR - Research Report) today and set a price target of $20.00. The company's shares …

advfn.com

$12917.50
OFF

Vor Biopharma Inc. (NYSE:VOR) Insider Sells $12,917.50 In Stock

4 weeks from now

12 hours ago · Vor Biopharma Inc. (NYSE:VOR - Get Free Report) insider Eyal C. Attar sold 10,334 shares of the business's stock in a transaction dated Friday, December 27th. ... HC …

marketbeat.com

$55
OFF

Vor Biopharma Secures $55.6M For Cancer Therapy Trials - Yahoo …

4 weeks from now

4 days ago · The latest announcement is out from Vor Biopharma ( (VOR) ). Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue …

yahoo.com

$17.50
OFF

Vor Biopharma’s (VOR) “Outperform” Rating Reiterated At Wedbush

4 weeks from now

Nov 12, 2024 · VOR has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research …

defenseworld.net

$48
OFF

NewAmsterdam Pharma Initiated With A Buy At H.C. Wainwright

4 weeks from now

1 day ago · H.C. Wainwright analyst Ed Arce initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $48 price target NewAmsterdam is a late-stage biopharma …

nasdaq.com

FAQs about Vor Biopharma’s (VOR) Buy Rating Reiterated at HC Wainwright Coupon?

Can HC Wainwright buy Vor BioPharma (VOR – free report)?

HC Wainwright reaffirmed their buy rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $17.50 price target on the stock. A number of other equities analysts also recently issued reports on the stock. ...

Should you buy Vor BioPharma (VOR – research report)?

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vor Biopharma ( VOR – Research Report ), with a price target of $17.50. The company’s shares closed yesterday at $2.57. According to TipRanks, Ramakanth is an analyst with an average return of -20.5% and a 23.02% success rate. ...

What is a good price target for Vor BioPharma?

The firm currently has a $17.50 price target on the stock. A number of other equities analysts also recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday. ...

Who owns Vor BioPharma?

Finally, Rosalind Advisors Inc. purchased a new stake in Vor Biopharma during the third quarter valued at about $54,000. 97.29% of the stock is owned by institutional investors. (Get Free Report) Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. ...

What is Vor BioPharma (VOR)?

More about Vor Biopharma Vor Bio is a clinical-stage cell and genome engineering company focused on transforming the treatment of blood cancers by engineering hematopoietic stem cells to enhance targeted therapies post-transplant. Learn more about VOR stock on TipRanks’ Stock Analysis page. ...

Should you buy Ramakanth (Vor BioPharma)?

According to TipRanks, Ramakanth has an average return of -17.1% and a 28.06% success rate on recommended stocks. Currently, the analyst consensus on Vor Biopharma is a Strong Buy with an average price target of $16.44, which is a 271.95% upside from current levels. ...